We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord

Ticker
CRVO

Price
6.85
Stock movement down
-0.01 (-0.11%)
Company name
CervoMed Inc.
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
80.24M
Ent value
-
Price/Sales
-
Price/Book
-
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
-46.05%
3 year return
-3.78%
5 year return
-35.25%
10 year return
-54.95%
Last updated: 2025-09-12

iO Charts is a Seeking Alpha partner

DIVIDENDS

CRVO does not pay dividends or no data was received

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales-
Price to Book-
EV to Sales-

iO Charts is a Seeking Alpha partner

FINANCIALS

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open9.12
Daily high9.52
Daily low9.04
Daily Volume68K
All-time high3375000000.00
1y analyst estimate21.50
Beta-6.24
EPS (TTM)-
Dividend per share-
Ex-div date-
Next earnings date-

Downside potential

Loading...
Downside potential data
CRVOS&P500
Current price drop from All-time high-100.00%-1.46%
Highest price drop-100.00%-56.47%
Date of highest drop21 Aug 20259 Mar 2009
Avg drop from high-91.40%-10.99%
Avg time to new high415 days12 days
Max time to new high5344 days1805 days

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

COMPANY DETAILS
CRVO (CervoMed Inc.) company logo
Marketcap
80.24M
Marketcap category
Small-cap
Description
CervoMed Inc., a a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in DLB and certain other major neurological disorders. It is being evaluated in a Phase 2b study in patients with DLB. The company develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.
Employees
15
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

UNDERSTAND THE BUSINESS
Loading...